Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience
CONCLUSION: Although no statistically significant differences have been found in TT or PFS, it would be more advisable to use BFIR scheme due to its better results in OS and toxicity profile.PMID:34664108 | DOI:10.1007/s00228-021-03235-5
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Raquel Claramunt Garc ía Carmen Luc ía Muñoz Cid Andr és Sánchez Ruiz Juan Francisco Mar ín Pozo Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | Statistics | Study | Toxicology